Diprovocims

A New and Exceptionally Potent Class of Toll-like Receptor Agonists

Matthew D. Morin, Ying Wang, Brian T. Jones, Yuto Mifune, Lijing Su, He-Xin Shi, Eva Marie Y. Moresco, Hong Zhang, Bruce A Beutler, Dale L. Boger

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A screen conducted with nearly 100000 compounds and a surrogate functional assay for stimulation of an immune response that measured the release of TNF-α from treated human THP-1 myeloid cells differentiated along the macrophage line led to the discovery of the diprovocims. Unique to these efforts and of special interest, the screening leads for this new class of activators of an immune response came from a compound library designed to promote cell-surface receptor dimerization. Subsequent comprehensive structure-activity relationship studies improved the potency 800-fold over that of the screening leads, providing diprovocim-1 and diprovocim-2. The diprovocims act by inducing cell-surface toll-like receptor (TLR)-2 dimerization and activation with TLR1 (TLR1/TLR2 agonist), bear no structural similarity to any known natural or synthetic TLR agonist, and are easy to prepare and synthetically modify, and selected members are active in both human and murine systems. The most potent diprovocim (3, diprovocim-1) elicits full agonist activity at extraordinarily low concentrations (EC50 = 110 pM) in human THP-1 cells, being more potent than the naturally derived TLR1/TLR2 agonist Pam3CSK4 or any other known small molecule TLR agonist.

Original languageEnglish (US)
JournalJournal of the American Chemical Society
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Dimerization
Toll-Like Receptors
Screening
Toll-Like Receptor 2
Macrophages
Cell Surface Receptors
Assays
Chemical activation
Myeloid Cells
Structure-Activity Relationship
Libraries
Molecules

ASJC Scopus subject areas

  • Catalysis
  • Chemistry(all)
  • Biochemistry
  • Colloid and Surface Chemistry

Cite this

Diprovocims : A New and Exceptionally Potent Class of Toll-like Receptor Agonists. / Morin, Matthew D.; Wang, Ying; Jones, Brian T.; Mifune, Yuto; Su, Lijing; Shi, He-Xin; Moresco, Eva Marie Y.; Zhang, Hong; Beutler, Bruce A; Boger, Dale L.

In: Journal of the American Chemical Society, 01.01.2018.

Research output: Contribution to journalArticle

Morin, Matthew D. ; Wang, Ying ; Jones, Brian T. ; Mifune, Yuto ; Su, Lijing ; Shi, He-Xin ; Moresco, Eva Marie Y. ; Zhang, Hong ; Beutler, Bruce A ; Boger, Dale L. / Diprovocims : A New and Exceptionally Potent Class of Toll-like Receptor Agonists. In: Journal of the American Chemical Society. 2018.
@article{c5942ed6170c440381bca3852ef6b835,
title = "Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists",
abstract = "A screen conducted with nearly 100000 compounds and a surrogate functional assay for stimulation of an immune response that measured the release of TNF-α from treated human THP-1 myeloid cells differentiated along the macrophage line led to the discovery of the diprovocims. Unique to these efforts and of special interest, the screening leads for this new class of activators of an immune response came from a compound library designed to promote cell-surface receptor dimerization. Subsequent comprehensive structure-activity relationship studies improved the potency 800-fold over that of the screening leads, providing diprovocim-1 and diprovocim-2. The diprovocims act by inducing cell-surface toll-like receptor (TLR)-2 dimerization and activation with TLR1 (TLR1/TLR2 agonist), bear no structural similarity to any known natural or synthetic TLR agonist, and are easy to prepare and synthetically modify, and selected members are active in both human and murine systems. The most potent diprovocim (3, diprovocim-1) elicits full agonist activity at extraordinarily low concentrations (EC50 = 110 pM) in human THP-1 cells, being more potent than the naturally derived TLR1/TLR2 agonist Pam3CSK4 or any other known small molecule TLR agonist.",
author = "Morin, {Matthew D.} and Ying Wang and Jones, {Brian T.} and Yuto Mifune and Lijing Su and He-Xin Shi and Moresco, {Eva Marie Y.} and Hong Zhang and Beutler, {Bruce A} and Boger, {Dale L.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1021/jacs.8b09223",
language = "English (US)",
journal = "Journal of the American Chemical Society",
issn = "0002-7863",
publisher = "American Chemical Society",

}

TY - JOUR

T1 - Diprovocims

T2 - A New and Exceptionally Potent Class of Toll-like Receptor Agonists

AU - Morin, Matthew D.

AU - Wang, Ying

AU - Jones, Brian T.

AU - Mifune, Yuto

AU - Su, Lijing

AU - Shi, He-Xin

AU - Moresco, Eva Marie Y.

AU - Zhang, Hong

AU - Beutler, Bruce A

AU - Boger, Dale L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A screen conducted with nearly 100000 compounds and a surrogate functional assay for stimulation of an immune response that measured the release of TNF-α from treated human THP-1 myeloid cells differentiated along the macrophage line led to the discovery of the diprovocims. Unique to these efforts and of special interest, the screening leads for this new class of activators of an immune response came from a compound library designed to promote cell-surface receptor dimerization. Subsequent comprehensive structure-activity relationship studies improved the potency 800-fold over that of the screening leads, providing diprovocim-1 and diprovocim-2. The diprovocims act by inducing cell-surface toll-like receptor (TLR)-2 dimerization and activation with TLR1 (TLR1/TLR2 agonist), bear no structural similarity to any known natural or synthetic TLR agonist, and are easy to prepare and synthetically modify, and selected members are active in both human and murine systems. The most potent diprovocim (3, diprovocim-1) elicits full agonist activity at extraordinarily low concentrations (EC50 = 110 pM) in human THP-1 cells, being more potent than the naturally derived TLR1/TLR2 agonist Pam3CSK4 or any other known small molecule TLR agonist.

AB - A screen conducted with nearly 100000 compounds and a surrogate functional assay for stimulation of an immune response that measured the release of TNF-α from treated human THP-1 myeloid cells differentiated along the macrophage line led to the discovery of the diprovocims. Unique to these efforts and of special interest, the screening leads for this new class of activators of an immune response came from a compound library designed to promote cell-surface receptor dimerization. Subsequent comprehensive structure-activity relationship studies improved the potency 800-fold over that of the screening leads, providing diprovocim-1 and diprovocim-2. The diprovocims act by inducing cell-surface toll-like receptor (TLR)-2 dimerization and activation with TLR1 (TLR1/TLR2 agonist), bear no structural similarity to any known natural or synthetic TLR agonist, and are easy to prepare and synthetically modify, and selected members are active in both human and murine systems. The most potent diprovocim (3, diprovocim-1) elicits full agonist activity at extraordinarily low concentrations (EC50 = 110 pM) in human THP-1 cells, being more potent than the naturally derived TLR1/TLR2 agonist Pam3CSK4 or any other known small molecule TLR agonist.

UR - http://www.scopus.com/inward/record.url?scp=85055102576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055102576&partnerID=8YFLogxK

U2 - 10.1021/jacs.8b09223

DO - 10.1021/jacs.8b09223

M3 - Article

JO - Journal of the American Chemical Society

JF - Journal of the American Chemical Society

SN - 0002-7863

ER -